Education
About Us
Working with TipRanks
Follow Us
Saniona AB (DE:30S)
FRANKFURT:30S
30S Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.18 - €0.82
Previous CloseN/A
Volume0.00
Average Volume (3M)3.00
Market Cap
€101.97M
Enterprise Value€791.42M
Total Cash (Recent Filing)€303.26M
Total Debt (Recent Filing)kr10.50M
Price to Earnings (P/E)4.8
Beta0.41
Next Earnings
Aug 28, 2025EPS EstimateN/A
Last Dividend Ex-Date
Oct 20, 2016Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding135,521,840
10 Day Avg. Volume9
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)3.86
Price to Sales (P/S)0.00
P/FCF Ratio4.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Saniona AB News
30S FAQ
What was Saniona AB’s price range in the past 12 months?
Saniona AB lowest stock price was €0.18 and its highest was €0.82 in the past 12 months.
What is Saniona AB’s market cap?
Saniona AB’s market cap is €101.97M.
When is Saniona AB’s upcoming earnings report date?
Saniona AB’s upcoming earnings report date is Aug 28, 2025 which is in 85 days.
How were Saniona AB’s earnings last quarter?
Saniona AB released its earnings results on May 28, 2025. The company reported €0.015 earnings per share for the quarter, beating the consensus estimate of N/A by €0.015.
Is Saniona AB overvalued?
According to Wall Street analysts Saniona AB’s price is currently Overvalued.
Does Saniona AB pay dividends?
Saniona AB pays a Notavailable dividend of €0.009 which represents an annual dividend yield of N/A. See more information on Saniona AB dividends here
What is Saniona AB’s EPS estimate?
Saniona AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Saniona AB have?
Saniona AB has 135,521,840 shares outstanding.
What happened to Saniona AB’s price movement after its last earnings report?
Saniona AB reported an EPS of €0.015 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 5.263%.
Which hedge fund is a major shareholder of Saniona AB?
Currently, no hedge funds are holding shares in DE:30S
Company Description
Saniona AB
Saniona AB (publ), a rare disease biopharmaceutical company, engages in the research, development, and commercialization of treatments for the central nervous system in Denmark. The company's products include Tesofensine, a monoamine reuptake inhibitor; and Tesomet, a fixed dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity. It also develops SAN711, which is in Phase 1 clinical stage for rare neuropathic disorders; SAN903 that is in preclinical stage for rare inflammatory, fibrotic, and hematological disorders. The company has research and collaboration agreements with Boehringer Ingelheim International GmbH; license agreement with Productos Medix, S.A. de C.V.; research services agreement and a collaboration agreement with Cephagenix ApS. Saniona AB (publ) was founded in 2011 and is headquartered in Glostrup, Denmark.
Technical Analysis
SynAct Pharma AB
―
Xbrane Biopharma AB
―
IRLAB Therapeutics AB Class A
―
Guard Therapeutics International AB
―
Xspray Pharma AB
―